CN105079096A - Traditional Chinese medicine composition capable of reducing toxicity and enhancing efficacy for postoperative adjuvant treatment of gastric cancer - Google Patents
Traditional Chinese medicine composition capable of reducing toxicity and enhancing efficacy for postoperative adjuvant treatment of gastric cancer Download PDFInfo
- Publication number
- CN105079096A CN105079096A CN201510559408.7A CN201510559408A CN105079096A CN 105079096 A CN105079096 A CN 105079096A CN 201510559408 A CN201510559408 A CN 201510559408A CN 105079096 A CN105079096 A CN 105079096A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine composition
- parts
- gastric cancer
- traditional chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a traditional Chinese medicine composition for adjuvant treatment of gastric cancer and a preparation method of the traditional Chinese medicine composition. The traditional Chinese medicine composition mainly comprises a panaxoside Rg3 monomer, salidroside, schisandrin B, taraxerol and an extract from the peel of juglans mandshurica Maxim. The traditional Chinese medicine composition can be dissolved in glucose, sodium chloride, lactose, laevulose, xylitol and the like to serve as injection solvents, and has the advantages that the toxic and side effects are little, and the treatment effect is obvious.
Description
Technical field
The invention belongs to herbal mixture technical field, be specifically related to a kind of Chinese prescription for the treatment of gastric cancer.
Background technology
Gastric cancer is modal malignant tumor in digestive system, account for more than 95% of stomach malignancy, the 4th modal in the world cancer after pulmonary carcinoma, breast carcinoma and colorectal cancer, occupy the 3rd of whole world male malignancy sickness rate, the 4th of female malignant sickness rate, occupy cancer case fatality rate second.In recent years, along with deepening continuously of research, the treatment levels such as surgical operation, immunity and chemotherapy are improving constantly, gastric cancer declines to some extent in global total incidence rate, but situation allows of no optimist in developing country, sickness rate and case fatality rate still remain high, and about have the case of 2/3 to be distributed in developing country, and particularly the East Asian countries such as Chinese, Japanese are district occurred frequently.Because this sick onset concealment, grade malignancy are high, have the features such as poor prognosis, survival rate are low, it occurs and death toll is high pressure situation, and the annual new cases of China about 300,000 people, wherein death toll reaches about 170,000.In current inpatient, more than 90% is advanced gastric carcinoma, even if implement radical operation, within 5 years, survival rate is still hovered about 50%.
The treatment of current advanced gastric carcinoma is still to perform the operation into master, and chemotherapy is auxiliary Comprehensive Treatment mode.The supplemental treatment regimens of generally acknowledging in the world at present much comprises traditional chemotherapy and targeted therapy, but most somewhat expensive, toxic and side effects are comparatively large, and patient Chang Yin economic cause or severe complication be abandoning cure as immunologic function degression, bone marrow transplantation, gastricism, cardiac toxicity etc.Life cycle is extended significantly not yet after most of patients treatment with chemotherapy, targeted therapy.The traditional medicine of China has the history of several thousand, and opinion is original, and particularly Chinese medicine effect in the immune system regulating patient is comparatively large, is also more and more confirmed by experiments for antineoplastic effect.Just because the toxic and side effects of Chinese medicine is little, evident in efficacy, application in TCM has become in the treatment of gastric cancer the focus that common people pay close attention in recent years.
Ginsenoside Rg3 is a kind of effective monomer composition extracted from Chinese medicine Radix Ginseng, and correlational study shows that it has antiinflammatory, inhibition tumor cell transfer, raising chemotherapy drug effect, inhibition tumor cell propagation and induces the effects such as its tune is died, the generation of Tumor suppression new vessels.Bibliographical information ginsenoside is had to play potentiation in the chemotherapy of the tumor patients such as pulmonary carcinoma, breast carcinoma, gastric cancer, hepatocarcinoma, and deficiency of vital energy symptom after obviously can improving chemotherapy, improve immunity of organisms and life quality.The Chinese medicine preparation Shenyi capsule be developed into by this monomer achieves certain curative effect in the treatment of the malignant tumor such as auxiliary pulmonary carcinoma, gastric cancer.
Radix Rhodiolae is Crassulaceae Rhodida plant, has than more rich wild resource in China.One of its principle active component is a kind of compound-rhodioside with high immunological activity.Rhodioside has growth inhibited, differentiation-inducing and promotion apoptotic effect to kinds of tumor cells.It also has the effect of immunity moderation function, Tumor suppression angiogenesis simultaneously.Rhodioside can the effect of inhibition tumor cell migration to have experimentation to show, lowering MMP2 albumen may be one of action target spot of its Tumor suppression infiltration metastasis.
Schisandrin B is the main component of lignanoid in magnoliaceae schisandra, has very strong biological activity.Research display: schisandrin B can the liver protecting, has the ability of stronger scavenging activated oxygen, has resisting fatigue, strengthens immunity and the pharmacological action such as antidotal.In recent years bibliographical information its also there is certain antitumor action, the Infiltration and metastasis of breast cancer cell can be affected by suppressing Epithelial and stromal to transform, suppressing carcinoma of gallbladder by cycle of regulate tumor cell and apoptosis, suppressing gastric cancer by lowering the expression of cyclinD1mRNA.
Semen Caryae Cathayensis, Juglandaceae Juglans broad leaved and deciduous broad leaved arbor also known as Juglans mandshurica, mainly be distributed in Eastern Heilongjiang Province, the mountain areas such as the Xiaoxinanlin Mountains, Wanda Mountain, master ridge and Zhang Guangcai ridge, there is distribution in the Eastern Mountain Area in China Jilin and Liaoning, the Inner Mongol, Shanxi, Henan, Hebei.Bark name Cortex Juglandis mandshuricae, bitter in the mouth is cold in nature, has effect of heat clearing away, removing toxic substances, dysentery relieving, improving eyesight, cure mainly have loose bowels, dysentery, leucorrhea, conjunctival congestion.Juglans mandshurica contains the chemical substances such as naphthoquinone, kernel feature space, flavonoid glycoside, ellagic acid, gallic acid and liposoluble ingredient.Modern pharmacology research shows, Juglans mandshurica has antitumor, antioxidation, AntiHIV1 RT activity, analgesia, the effect such as antibacterial.Cortex Juglandis mandshuricae is the traditional anti-tumor drug of folks of china, and it contains multiple anti-tumor active ingredient.
Alnulin and Taraxeryl acetate are the triterpenoid compound extracted from Herba Taraxaci, multiple triterpenoid compound has antitumaous effect, therefore anticancer, the anti-cancer mechanism of Herba Taraxaci may with suppress generation, the Tumor suppression angiogenic growth of free radical and cancerigenic factor and improve immunity of organisms etc. relevant.The polysaccharide component of Herba Taraxaci has good antitumor action, and its mechanism is relevant with promotion apoptosis of tumor cells.There are some researches show that the gastric cancer BGC823 cell MMP2 gene expression through Herba Taraxaci process declines, and reduce with the increase of Herba Taraxaci concentration.Prompting Herba Taraxaci can suppress migration, the invasion and attack effect of gastric cancer BGC823 cell, and its mechanism may to lower MMP2 gene expression relevant with Herba Taraxaci.In stomach cancer cell experiment, alnulin has more significant antitumaous effect than Taraxeryl acetate.As a kind of nontoxic and have the antitumor drug of various active, Herba Taraxaci great exploitation potential for its, the anticancer function of Herba Taraxaci also studied person gradually paid close attention to.
the content of inventiontechnical problem to be solved by this invention is to provide one group of little, economic, effective preparation method of gastric cancer being carried out to auxiliary treatment Chinese medicine composition and above-mentioned Chinese medicine composition of toxic and side effects.
For achieving the above object, the present invention is by the following technical solutions:
A kind of Chinese medicine composition of postoperative gastric cancer auxiliary treatment attenuation synergistic, the component with following parts by weight obtains: Ginsenoside Rg3 monomer 6 ~ 12 parts, rhodioside 16 ~ 24 parts, schisandrin B 40 ~ 50 parts, alnulin 16 ~ 24 parts, manchurian walnut bark extract 40 ~ 60 parts.
Manchurian walnut bark extract is extracted by following manner: precision takes Cortex Juglandis mandshuricae sample 5000g, take ether as lixiviating solution, and lixiviating solution volume and sample quality ratio are 10: 1 (ml/g).Extract 3 times after soaked overnight, about 8h at every turn, Rotary Evaporators reclaims ether layer and retains; Remaining residual medicinal chloroform extraction 3 times, about 8h at every turn, Rotary Evaporators reclaims chloroform layer.All the other can be bought by market or purify voluntarily in conventional manner.
Described drug component mixing is made into dry powder drug combination.
As the most preferred technical scheme of one of the present invention, the Chinese medicine composition of described postoperative gastric cancer auxiliary treatment attenuation synergistic is obtained by following component: Ginsenoside Rg3 monomer 8 parts, rhodioside 20 parts, schisandrin B 50 parts, alnulin 22 parts, manchurian walnut bark extract 45 parts.
The combination of said medicine monomer dry powder dissolves in glucose, sodium chloride, lactose, fructose, xylitol etc. as injection solvent.
A Chinese medicine composition for postoperative gastric cancer auxiliary treatment attenuation synergistic, said composition purifies with above-mentioned active ingredient of Chinese herbs to control into dry powder, is dissolved in the acceptable solvent of pharmaceutics, makes the acceptable dosage form of pharmaceutics.The method that extraction process of active component in the present invention can be produced according to art of pharmacy routine is purified voluntarily.During the various dosage form of medicine needed for the active fraction preparation of the Chinese medicine composition utilizing the present invention to obtain, the method can producing conventional medicine according to pharmaceutics is prepared.
Advantage of the present invention is: the present invention makes full use of the effective ingredient of Chinese medicine, makes the most significant medicine monomer of effect, improves the curative effect of Chinese medicine composition.Compared with the normal chemotherapy protocols of doctor trained in Western medicine prescription, drug regimen of the present invention has the advantages such as toxic and side effects is little, curative effect is obvious, and all pharmaceutical compositions mostly are our province main Chinese medicinal materials, draws materials conveniently, has significant economic and social benefit.
Describe technical scheme of the present invention by the following examples in detail, do not limit practical range of the present invention with this.
Detailed description of the invention
Embodiment 1
A kind of Chinese medicine composition of postoperative gastric cancer auxiliary treatment attenuation synergistic, this pharmaceutical composition comprises following raw materials according and makes according to parts by weight: Ginsenoside Rg3 8mg, rhodioside 18mg, schisandrin B 50mg, alnulin 20mg, manchurian walnut bark extract 45mg.Manchurian walnut bark extract is extracted by following manner: precision takes Cortex Juglandis mandshuricae sample 5000g, take ether as lixiviating solution, and lixiviating solution volume and sample quality ratio are 10: 1 (ml/g).Extract 3 times after soaked overnight, about 8h at every turn, Rotary Evaporators reclaims ether layer and retains; Remaining residual medicinal chloroform extraction 3 times, about 8h at every turn, Rotary Evaporators reclaims chloroform layer.All the other components can be bought by market or purify voluntarily in conventional manner.
Described drug component mixing is made into dry powder drug combination.
Embodiment 2
A kind of Chinese medicine composition of postoperative gastric cancer auxiliary treatment attenuation synergistic, this pharmaceutical composition comprises following raw materials according and makes according to parts by weight: Ginsenoside Rg3 6mg, rhodioside 20mg, schisandrin B 40mg, alnulin 18mg, manchurian walnut bark extract 45mg.Manchurian walnut bark extract extracting method is with embodiment 1.Described drug regimen mixing is made into the combination of medicine monomer dry powder.
Experimental example 3
MTT colorimetric method for determining stomach cancer cell line is inhibitory rate of cell growth after the effect of said medicine group, and experimental result shows that vitro growth rates is starkly lower than matched group, and suppression ratio increases with the prolongation of action time.
Claims (2)
1. the preparation method of the Chinese medicine composition of a postoperative gastric cancer auxiliary treatment attenuation synergistic, it is characterized in that: obtained by the component of following parts by weight: Ginsenoside Rg3 monomer 6 ~ 12 parts, rhodioside 16 ~ 24 parts, schisandrin B 40 ~ 50 parts, alnulin 16 ~ 24 parts, manchurian walnut bark extract 40 ~ 60 parts, manchurian walnut bark extract is extracted by following manner: precision takes Cortex Juglandis mandshuricae sample 5000g, take ether as lixiviating solution, lixiviating solution volume and sample quality are 10: 1 than ml/g, extract 3 times after soaked overnight, each about 8h, Rotary Evaporators reclaims ether layer and retains, remaining residual medicinal chloroform extraction 3 times, about 8h at every turn, Rotary Evaporators reclaims chloroform layer, and all the other components can be bought by market or purify voluntarily in conventional manner, and described drug component mixing is made into dry powder drug combination.
2. the Chinese medicine composition of postoperative gastric cancer auxiliary treatment attenuation synergistic is prepared by the method for claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510559408.7A CN105079096A (en) | 2015-09-07 | 2015-09-07 | Traditional Chinese medicine composition capable of reducing toxicity and enhancing efficacy for postoperative adjuvant treatment of gastric cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510559408.7A CN105079096A (en) | 2015-09-07 | 2015-09-07 | Traditional Chinese medicine composition capable of reducing toxicity and enhancing efficacy for postoperative adjuvant treatment of gastric cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105079096A true CN105079096A (en) | 2015-11-25 |
Family
ID=54561027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510559408.7A Pending CN105079096A (en) | 2015-09-07 | 2015-09-07 | Traditional Chinese medicine composition capable of reducing toxicity and enhancing efficacy for postoperative adjuvant treatment of gastric cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105079096A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1621037A (en) * | 2003-11-29 | 2005-06-01 | 胡汛 | Application of Schisandrin-B in preparing medicine for treating tumor |
| CN1911329A (en) * | 2006-08-11 | 2007-02-14 | 杨德华 | Traditional Chinese medicine composition for preventing and/or adjuvant therapy of malignant tumor |
| CN103127212A (en) * | 2011-11-29 | 2013-06-05 | 吉林大学 | Application of walnut Cortex Juglandis Mandshuricae in medicine for gastric cancer |
| CN104257673A (en) * | 2014-09-29 | 2015-01-07 | 天利康（天津）科技有限公司 | Application of salidroside |
-
2015
- 2015-09-07 CN CN201510559408.7A patent/CN105079096A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1621037A (en) * | 2003-11-29 | 2005-06-01 | 胡汛 | Application of Schisandrin-B in preparing medicine for treating tumor |
| CN1911329A (en) * | 2006-08-11 | 2007-02-14 | 杨德华 | Traditional Chinese medicine composition for preventing and/or adjuvant therapy of malignant tumor |
| CN103127212A (en) * | 2011-11-29 | 2013-06-05 | 吉林大学 | Application of walnut Cortex Juglandis Mandshuricae in medicine for gastric cancer |
| CN104257673A (en) * | 2014-09-29 | 2015-01-07 | 天利康（天津）科技有限公司 | Application of salidroside |
Non-Patent Citations (1)
| Title |
|---|
| 谭宝等: "蒲公英萜醇和乙酰蒲公英萜醇对胃癌细胞株AGS细胞周期和凋亡的影响", 《中西医结合学报》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9439874B2 (en) | Food composition for nourishing, maintaining and cultivating a variety of stem cells and a method for manufacturing the same | |
| CN103768534B (en) | A kind of Chinese medicine composition with antitumor activity | |
| CN103012356B (en) | Compound with alpha-glycosidase inhibitory activity, as well as preparation method and application of compound | |
| CN101850032B (en) | Anti-tumor traditional Chinese medicine composition and preparation method and application thereof | |
| CN102432620A (en) | Resveratrol tetramer compound, its preparation method and application | |
| CN104173451A (en) | Application of natural pharmaceutical composition in blood glucose-reducing drugs and health food | |
| CN108434223A (en) | A kind of composition for treating the Chinese medical extract of cancer of pancreas | |
| CN1775267A (en) | Kaikoujian extract, Its preparing method and use | |
| CN105399794B (en) | Fructus momordicae triterpene saponin and salt thereof, preparation method and applications of fructus momordicae triterpene saponin and salt thereof, and pharmaceutical composition containing fructus momordicae triterpene saponin and salt thereof | |
| CN103191167B (en) | Application of eupatorium Chinese | |
| CN109806304A (en) | The preparation method of three leaf raspberry plant extracts and its pharmaceutical composition and anti-trichina purposes | |
| CN103385931B (en) | Blood-sugar-lowering medicine composition | |
| CN105031468A (en) | Sharpleaf galangal fruit extract capable of treating chronic kidney diseases and applications thereof | |
| CN104189782A (en) | Anti-tumor medicament composition | |
| CN105079096A (en) | Traditional Chinese medicine composition capable of reducing toxicity and enhancing efficacy for postoperative adjuvant treatment of gastric cancer | |
| CN101940614A (en) | Application of juglans mandshurica maxim. ethyl acetate part in preparing alpha-glucosidase inhibitor medicament | |
| CN103251706A (en) | Traditional chinese medicine composition | |
| Lai et al. | Analysis of anti-cancer traditional Chinese medicine injections based on market performance | |
| CN100411663C (en) | Anticancer compound Chinese medicine powder and its preparing method | |
| CN103800351A (en) | Pharmaceutical application of akebin E | |
| CN104547026A (en) | Preparation method and application of salvia miltiorrhiza leave and panax pseudo-ginseng extract | |
| CN103417620A (en) | Application of serrate rabdosia herb extractive serving as STAT3 signal specificity inhibiter in preparation of anti-tumor drug | |
| CN103202886A (en) | Traditional chinese medicine composition and preparation method thereof | |
| CN103191162B (en) | Application of fructus akebiae extract in preparation of drug for treating primary hepatic carcinoma | |
| CN103585485B (en) | Anticancer medicine and preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20151125 |
|
| WD01 | Invention patent application deemed withdrawn after publication |